Human Factor IX (Factor 9) Deficient Serum

<strong>Human Factor IX (Factor 9) Deficient Serum</strong>_x000D_ <strong>Catalog number:</strong> B2015447_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mL_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> N/A_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Coagulation Factor 9, Coagulation Factor IX, Factor IX, Christmas Disease Factor, Christmas Factor, F9, FIX, Haemophilia B Factor, HEMB, MGC129641, MGC129642, P19, Plasma Thromboplastic Component, PTC_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Pegg CL, Zacchi LF, Recinos DR, Howard CB, Schulz BL. Identification of novel glycosylation events on human serum-derived factor IX Glycoconj J. 2020 Aug;37(4):471-483._x000D_ 2: Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing Lancet. 2021 Feb 13;397(10274):630-640._x000D_ 3: Silveira A. Postprandial triglycerides and blood coagulation Exp Clin Endocrinol Diabetes. 2001;109(4):S527-32._x000D_ 4: Kiykim E, Zubarioglu T, Cansever MS, Celkan T, Häberle J, Aktuglu Zeybek AC. Coagulation Disturbances in Patients with Argininemia Acta Haematol. 2018;140(4):221-225._x000D_ 5: Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism Blood. 1990 Aug 15;76(4):731-6._x000D_ 6: Letchumanan I, Gopinath SCB, Md Arshad MK, Anbu P, Lakshmipriya T. Gold nano-urchin integrated label-free amperometric aptasensing human blood clotting factor IX: A prognosticative approach for "Royal disease" Biosens Bioelectron. 2019 Apr 15;131:128-135._x000D_ 7: Tsui LV, Kelly M, Zayek N, Rojas V, Ho K, Ge Y, Moskalenko M, Mondesire J, Davis J, Roey MV, Dull T, McArthur JG. Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector Nat Biotechnol. 2002 Jan;20(1):53-7._x000D_ 8: Simhadri VL, Hamasaki-Katagiri N, Tseng SC, Bentley AA, Zichel R, Hershko AY, Komar AA, Kimchi-Sarfaty C. Factor IX oligomerization underlies reduced activity upon disruption of physiological conditions Haemophilia. 2014 Mar;20(2):e157-63._x000D_ 9: Goedert JJ, Sarngadharan MG, Eyster ME, Weiss SH, Bodner AJ, Gallo RC, Blattner WA. Antibodies reactive with human T cell leukemia viruses in the serum of hemophiliacs receiving factor VIII concentrate Blood. 1985 Feb;65(2):492-5._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/34651201">10: Preijers T, van Spengler MWF, Meijer K, Fijnvandraat K, Fischer K, Leebeek FWG, Cnossen MH, Mathôt RAA. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients Eur J Clin Pharmacol. 2022 Feb;78(2):237-249. </a>_x000D_ _x000D_ <strong>Products Related to Human Factor IX (Factor 9) Deficient Serum can be found at</strong> <a href="https://moleculardepot.com/product-category/Biofluids/"> Biofluids</a>